$468 $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

A series of state and federal lawsuits challenging coverage exclusions for obesity drugs and procedures are testing the ...

In a leadership shakeup, the diet company says CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a ...

We know there are several physical risks associated with the drugs, but some are now beginning to question whether there are ...

Time-restricted eating may improve blood glucose control and help reduce fat when coupled with standard nutritional ...

Weight loss drugs are rising in popularity. Savannah doctors weigh in on risks and benefits ...

An analyst waxed bullish on the company's leading pipeline program.

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

As told to Alexia Dellner Weight loss drugs like Ozempic and Wegovy have become a hot topic of late, with everyone from ...

Roche argued that its obesity medications would prove to have advantages over its rivals’ — and that the demand for weight ...

Per Dr. Wheeler, some signs that metformin may not be working are persistently high blood glucose levels and no improvement ...